Member access

4-Traders Homepage  >  Shares  >  Swiss Exchange  >  Actelion Ltd    ATLN   CH0010532478

ACTELION LTD (ATLN)

59
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Actelion Ltd
Develops, produces and markets pharmaceutical drugs

Actelion Ltd. operates as a holding company with interests in developing, producing and marketing pharmaceutical drugs.

It is a biopharmaceutical company, which focuses on the drug discovery, development, registration, production and commercialization of innovative drugs for diseases with significant unmet medical needs.

The company's portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications.

It has treatments for specialist diseases, including Type 1 Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients suffering from systemic sclerosis and mycosis fungoides in patients with cutaneous T-cell lymphoma.

The company products include Tracleer (bosentan), Zavesca (miglustat), Ventavis (iloprost), Veletri (epoprostenol for injection), Valchlor and Opsumit (macitentan).

Actelion was founded by Jean-Paul Clozel, Martine Clozel, Walter Fischli, André J. Mueller, and Thomas Widmann on December 17, 1997 and is headquartered in Allschwil, Switzerland.
Sales per Businesses
20132014Delta
CHF (in Million)%CHF (in Million)%
Drugs1,786100%1,958100% +8.79%
Sales per Regions
20132014Delta
CHF (in Million)%CHF (in Million)%
United States767.9643%879.2444.9% +12.66%
Europe632.0635.4%687.8235.1% +8.11%
Other356.6620%360.5218.4% +1.07%
Switzerland29.061.6%30.301.5% +4.12%
Managers
NameAgeSinceTitle
Jean-Paul Clozel601997Chief Executive Officer & Executive Director
Jean-Pierre Garnier682011Chairman
Otto Schwarz602008Chief Operating Officer & Executive Vice President
André C. Muller, MBA522013Chief Financial Officer & Executive Vice President
Martine Clozel, MD601997Chief Scientific Officer & Senior Vice President
Guy Braunstein MD, PhD592009Executive VP & Head-Global Clinical Development
Michael Jacobi, PhD622009Non-Executive Director
Jean Pierre Malo CFA, MBA61-Non-Executive Director
Juhani Anttila61-Non-Executive Director
Robert J. Bertolini, CPA52-Non-Executive Director
Shareholders
NameShares%
BlackRock Investment Management (UK) Ltd. 6,169,763 5.41%
Rudolf Maag, MBA 6,067,305 5.32%
Jean-Paul Clozel, MD 5,281,544 4.63%
Orbis Investment Management Ltd. 3,568,489 3.13%
Actelion Ltd. 3,457,446 3.03%
Fidelity Management & Research Co. 3,117,028 2.73%
Wellington Management Co. LLP 2,453,084 2.15%
Artisan Partners LP 2,390,217 2.09%
Bellevue Asset Management AG 2,307,513 2.02%
Norges Bank Investment Management 2,025,137 1.77%
Holdings
NameShares%Valuation
Actelion Ltd (ATLN) 3,457,4463.03%457,597,715 USD
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Advertisement
Sector Biotechnology & Medical Research
Growth (Revenue) Profitability
ACTELION LTD
SHANGHAI RAAS BLO..
-
MEDIVATION INC
INTERCEPT PHARMAC..
HUALAN BIOLOGICAL..
TONGHUA DONGBAO P..
BLUEBIRD BIO INC
BEIJING SL PHARMA..
RECEPTOS INC
GENMAB A/S
ZHONGYUAN UNION C..
-
AGIOS PHARMACEUTI..
JUNO THERAPEUTICS..
-
DYAX CORP.
NEUROCRINE BIOSCI..
CLOVIS ONCOLOGY I..
ULTRAGENYX PHARMA..
-
CHINA BIOLOGIC PR..
GW PHARMACEUTICAL..
-
KITE PHARMA INC
Sector Biotechnology & Medical Research
Actelion Ltd : Connections
Avalon Advisors LLC
Cerenis Therapeutics, Inc.
ArgYou AG
CFA Institute
Newman's Own Foundation
Max Planck Institute For Biophysical Chemistry
Society of Financial Analysts of Houston
Immuno International AG
ValCrea AG
Martin Hilti Family Trust
Actelion Pharmaceuticals UK Ltd.
Anttila & Co. Advisors
Hilti AG
Company contact information
16 Gewerbestrasse
CH-4123 Allschwil, Basel-Landschaft
Switzerland

Phone : +41 61 565 65 65
Fax : +41 61 565 65 00
Internet : http://www.actelion.com
Markets and indexes
- SIX Swiss Exchange
- Main Standard
- SMI /
Stock Exchange Codes
- ISIN Code :  CH0010532478
- Bloomberg Code :  ATLN:VX
- Reuters Code :  ATLN.VX
- Datastream Code :  S:ATLN
© 2015 People , Fundamentals and Ownership    © 2015 Cofisem